PGEN
NASDAQ · Biotechnology
Precigen Inc
$7.72
+0.02 (+0.26%)
Performance
1D
—
1W
—
1M
—
3M
+39.86%
6M
+110.35%
1Y
+136.09%
YTD
+136.09%
Open$7.65
Previous Close$7.70
Day High$7.73
Day Low$7.52
52W High$7.95
52W Low$2.99
Volume—
Avg Volume3.84M
Market Cap2.82B
P/E Ratio—
EPS$-0.52
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$5.25
Above
RSI (14)
75.9
Overbought
Analyst Ratings
Strong Buy
9 analysts
Price Target
+840.0% upside
Current
$7.72
$7.72
Target
$72.57
$72.57
$43.64
$72.57 avg
$99.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.19M | 15.73M | 411.38M |
| Net Income | -290,031,366 | -366,921,885 | -34,816,902 |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% |
| EBITDA | -124,190,503 | -165,843,376 | -49,679,638 |
| Free Cash Flow | — | — | -21,385,787 |
| Rev Growth | -28.9% | -28.9% | +17.8% |
| Debt/Equity | 4.46 | 4.46 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |